Biologics and Conjugates CDMO Services
Porton Biologics and Conjugates CDMO Service Platform specializes in customized development services for Biologics and various novel conjugate drugs, including ADC, AOC, DAC, PDC, RDC, and others. With strategically co-located R&D centers and manufacturing facilities enabling efficient logistics and operational synergy, we provide global pharmaceutical companies and new drug R&D organizations with one-stop CMC solutions covering the entire process: drug ability assessment, conjugation technology development, OAR control, process and formulation development, process scale-up and manufacturing, analytical and quality research, IND filing support, and clinical drug manufacturing. We comprehensively address diverse CMC requirements of clients across all project stages and are committed to enabling earlier access to good medicines.
50+
Experienced Scientists
50+
Projects (IND/P1/P2/P3/NDA)
40+
Customers
Our Services
Conjugates
-
ADC
Antibody-Drug Conjugate -
AOC
-
DAC
-
PDC
-
RDC
Targeting-vehicle
Antibody
Peptide
Small Molecule
Linker
Cys (-SH): S-S, Maleimide Group (mc, mcc, etc.)
Lys (-NH2): Activated Acid(CO-OSu, etc.)
Short Peptide (VC, GFGG, etc.)
PEG
Click Chemistry
pH-Sensitivity (HN-CH2-O-, C+N-NH=CO-, Hydrazine, Carbonate)
Multi Branches
Payload
Cytotoxic Drugs
Oligonucleotides
Radionuclides
Fluorescers
PROTAC
Early Stage Development
mg ~ g Scale Library
Developability Assessment
Process Development
Payload-Linker Process Development
Targeting-vehicle Process Development
Bioconjugation and Purification Process Development
DP Formulation & Process Development
Manufacturing
Payload-Linker Manufacturing
Targeting-vehicle Manufacturing
DS Manufacturing
DP Manufacturing
Analytical Development and QC
Analytical Method Development & Validation
Release Testing
Stability Study
Registration Services
CMC Filing Dossier
Supporting and Communication During Filing Process
-
ADC
Antibody-Drug Conjugate
-
AOC
-
DAC
-
PDC
-
RDC
Antibody
Peptide
Small Molecule
Cys (-SH): S-S, Maleimide Group (mc, mcc, etc.)
Lys (-NH2): Activated Acid(CO-OSu, etc.)
Short Peptide (VC, GFGG, etc.)
PEG
Click Chemistry
pH-Sensitivity (HN-CH2-O-, C+N-NH=CO-, Hydrazine, Carbonate)
Multi Branches
Cytotoxic Drugs
Oligonucleotides
Radionuclides
Fluorescers
PROTAC
mg ~ g Scale Library
Developability Assessment
Payload-Linker Process Development
Targeting-vehicle Process Development
Bioconjugation and Purification Process Development
DP Formulation & Process Development
Payload-Linker Manufacturing
Targeting-vehicle Manufacturing
DS Manufacturing
DP Manufacturing
Analytical Method Development & Validation
Release Testing
Stability Study
CMC Filing Dossier
Supporting and Communication During Filing Process
Porton Sites
Cranbury, New Jersey
- Payload-Linker and Bioconjugation
- DS
- Non-GMP & GMP
- Non-HP & HP
- Payload-Linker (10~100 L)
- Bioconjugation (10 L, 200~500 L) Planning
Minhang, Shanghai
- DS
- Non-GMP
- Non-HP & HP
- Payload-Linker (20 L)
Fengxian, Shanghai
- DS
- GMP
- Non-HP & HP
- Payload-Linker (100 L)
Pudong, Shanghai
- DS & DP
- GMP
- Non-HP & HP
- Antibody (500~2000 L)
- Bioconjugation (200~500 L)
Case Studies
More
Antibody-Oligonucleotide Conjugates: From Conjugation Strategy to Purification and Analytical Control
Antibody-Oligo Conjugate (AOC), as an innovative targeted gene therapy biopharmaceutical, effectively integrates the targeting advantages of monoclonal antibodies and the gene regulatory functions of oligonucleotides, helping address key limitations in the inherent of traditional antibody drugs and nucleic acid drugs, and showing substantial clinical
More
FAQ: CMC Development Strategy for Oligonucleotides in AOCs
•How to reduce hydrolysis during SMCC conjugation? •Can SMCC conjugate after hydrolytic ring-opening? •How is OAR1 regulated during random SMCC conjugation? •Which strategy is preferred for siRNA linker conjugation: pre-annealing or post-annealing conjugation?
More
Biocatalysis Enables The Efficient Synthesis and Commercial Application of Unnatural Amino Acids (UAAs)
Biocatalysis is a pivotal enabler for the sustainable synthesis of unnatural amino acids. By integrating novel enzymes discovery, multi-enzyme cascades and chemo-enzymatic routes, Porton has established practical capabilities to address industry challenges in substrate specificity and enzyme stability. Moving forward, Porton remains dedicated to bridging the gap between laboratory innovation and industrial-scale application, providing customers with reliable, scalable and atom-efficient solutions for UAA production.
More
Dry Particle Coating for the Enhancement of API Flowability and Bulk Density
The mechanism of the dry particle coating and a short description of four coating techniques including comil, LabRAM, a high shear mixer and a jet mill are provided.
More
Process Development and Quality Research Strategy for Dual-Payload Conjugated Drugs
Process Development and Quality Research Strategy for Dual-Payload Conjugated Drugs
More
FAQ: Process Development Strategies for AOC Drugs
What is the mainstream conjugation process for antibodies and siRNA?
More
Optimization of Synthetic Process and Metal-Chelation Impurity Control Strategy for Complex Peptide-based RDCs
It fully demonstrates the strength of Porton's one-stop RDC service platform, excellent project management capabilities, and efficient production and operation.
More
The Perfect Integration of Immobilized Enzymes and Flow Chemistry: A Powerful Booster for the Commercialization of Biocatalysis Technology
Adhering to Porton’s core value of “Pursuing Excellence”, Porton biocatalysis team has designated "enzyme immobilization technology and its industrialization" as a core strategic technology.
More
Process Simulation Platform: Enabling Process Development and Scale-up of Active Pharmaceutical Ingredients
Porton Crystallization team has the capability to perform process simulation of unit operations, including solvent swap, crystallization, filtration and drying.
More
Optimizing Process Chemistry for Enhanced Pharmaceutical Manufacturing
Process Chemistry Optimization | Pharma Manufacturing
More
Expert Q&A: How to Efficiently Apply Preparative Chromatography in Drug Research
How to Efficiently Apply Preparative Chromatography in Drug Research
More
Biocatalysis: A Powerful and Possible Greener Tool for Chemists in the Pharmaceutical Industry
End-to-end Enzyme Solutions Efficient Screening & process Development Comprehensive Quality Control Extensive Successful Applications Cases Technological Innovation Enabled Cost Savings
More
News
MoreNews2026-07-03
Porton Delivers Dual-Payload ADC IND, Advancing Next-generation Conjugate Drug Development
More
News2026-07-02
Porton Highlights Integrated CDMO Capabilities at BIO International Convention 2026 and Celebrates Porton J-STAR's 30th Anniversary
More
News2026-06-25
Porton Concludes Productive Presence at CPHI China 2026
More
News2026-03-31
Porton Newsletter - March 2026 Recap
More
News2026-03-03
Porton Wins “2025 Best CRO” Award from Daewoong Pharma
More
News2026-02-28
Porton Newsletter - February 2026 Recap
More
News2026-02-03
Porton Newsletter - January 2026 Recap
More
News2026-01-09
Porton Newsletter - Q4 2025 Recap
More
News2026-01-08
A Porton Publication in ACS Journal on Polymorphic Crystallization Kinetics Study and Control
More
News2025-12-30
Porton Achieves EU QP Certification for Chongqing Manufacturing Facility
More
News2025-12-23
Porton&Nona: Strategic Partnership for Complex Antibody Therapy
More
News2025-11-27
Porton Pharma Solutions Ranks Among China's Top 100 Premier Pharmaceutical Suppliers and Top 10 in ESG Competitiveness
More
